Lexeo Therapeutics (LXEO) investor relations material

Company overview and program focus

• Focuses on genetic medicines for cardiovascular diseases, with lead programs in Friedreich's ataxia (FA) and PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM).

• LX2006 targets cardiac pathology in FA, showing improvements in both cardiac and neurologic symptoms.

• LX2020 addresses PKP2-ACM, with a completed phase I enrollment and data readout expected later this year.

• Early-stage cardiovascular programs are also in development.

Disease education and patient engagement

• Multi-channel education efforts include partnerships with societies, social media, and advocacy organizations.

• Emphasis on early cardiac diagnosis and coordinated care among specialties.

• Introduction of therapy expected to increase cardiologist engagement.

Clinical trial design and endpoints for LX2006

• LVMi is the primary cardiac measure, chosen for its precision and strong link to disease progression and mortality.

• Natural history shows minimal LVMi change over a year; significant reductions seen with treatment.

• Troponin elevation is considered an early marker for initiating therapy.

• Patients with normal LVMi but elevated troponin also benefit, supporting broader treatment eligibility.

• Durable improvements in both cardiac and neurologic endpoints observed, with potential for label expansion.